US 12,083,117 B2
Compositions and kits useful for treatment of respiratory illness
Kelly Lee Martin Schmeichel, Cincinnati, OH (US); Jayant Eknath Khanolkar, Surbiton (GB); Douglas William Gledhill, St. Charles, MO (US); Susan Elaine Criss, Maineville, OH (US); Niranjan Ramji, Mason, OH (US); Elaine Rose Costeines, Maineville, OH (US); Thomas Edward Huetter, West Chester, OH (US); Radhika R. Iyer, Mason, OH (US); and Daren K. Anness, Loveland, OH (US)
Assigned to The Procter & Gamble Company, Cincinnati, OH (US)
Filed by The Procter & Gamble Company, Cincinnati, OH (US)
Filed on Oct. 11, 2021, as Appl. No. 17/498,152.
Application 17/498,152 is a continuation of application No. 15/930,540, filed on May 13, 2020, granted, now 11,141,415.
Application 15/930,540 is a continuation of application No. 16/128,579, filed on Sep. 12, 2018, granted, now 10,688,089, issued on Jun. 23, 2020.
Application 16/128,579 is a continuation of application No. 15/384,369, filed on Dec. 20, 2016, granted, now 10,098,873, issued on Oct. 16, 2018.
Application 15/384,369 is a continuation of application No. 11/657,860, filed on Jan. 25, 2007, abandoned.
Application 11/657,860 is a continuation in part of application No. 11/408,299, filed on Apr. 21, 2006, granted, now 10,022,339, issued on Jul. 17, 2018.
Prior Publication US 2022/0023236 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/485 (2006.01); A61J 1/05 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/473 (2006.01); A61K 31/495 (2006.01); A61K 31/519 (2006.01); A61K 31/522 (2006.01); A61K 31/55 (2006.01); A61K 31/616 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01)
CPC A61K 31/485 (2013.01) [A61J 1/05 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/473 (2013.01); A61K 31/495 (2013.01); A61K 31/519 (2013.01); A61K 31/522 (2013.01); A61K 31/55 (2013.01); A61K 31/616 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01)] 9 Claims
 
1. A stable liquid composition in a clear bottle comprising:
a. from about 0.001% to about 0.5% of phenylephrine hydrochloride, by weight of the stable liquid composition;
b. flavoring agent comprising one or more non-aldehydic aesthetic agents;
c. sugar alcohol selected from glycerin, sorbitol, maltitol, mannitol, or mixtures thereof;
d. artificial sweetener selected from sodium saccharine, acesulfame potassium, sucralose, aspartame, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, cyclamates, or mixtures thereof; and
e. solvent selected from water, propylene glycol, ethanol, or mixtures thereof; wherein the composition comprises from about 40% to about 95% of total solvent, by weight of the stable liquid composition;
wherein the stable liquid composition has a pH of from about 2 to about 6.5;
wherein the stable liquid composition is a solution;
wherein the stable liquid composition comprises less than about 0.1% of total aldehydes, by weight of the stable liquid composition; and
wherein the clear bottle comprises a material selected from polyethylene terephthalate (PET), glycol-modified polyethylene terephthalate (PETG), oriented polypropylene (OPP), polyvinylchloride (PVC), polyvinylidene chloride (PVDC), nylon, polyethylene terephthalate polyester (PETP), polyphene, or combinations thereof.